Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors

被引：56

作者：

Armstrong, Terri S. ^{[1
,2
]}

Wen, Patrick Y. ^{[3
,4
]}

Gilbert, Mark R. ^{[2
]}

Schiff, David ^{[5
,6
,7
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Integrat Nursing Care, UTHSC SON, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA

[3] Brigham & Womens Hosp, Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA

[4] Brigham & Womens Hosp, Div Neurooncol, Dept Neurol, Boston, MA 02115 USA

[5] Univ Virginia, Dept Neurol, Charlottesville, VA USA

[6] Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA

[7] Univ Virginia, Dept Med Hematol Oncol, Charlottesville, VA USA

来源：

NEURO-ONCOLOGY | 2012年 / 14卷 / 10期

关键词：

brain tumors; chemotherapy; toxicity; PHASE-II TRIAL; ENDOTHELIAL GROWTH-FACTOR; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PATIENTS RECEIVING BEVACIZUMAB; SINGLE-AGENT BEVACIZUMAB; VENOUS THROMBOEMBOLISM; CANCER-PATIENTS; GLIOBLASTOMA-MULTIFORME; ANAPLASTIC ASTROCYTOMA; RADIATION-THERAPY;

D O I：

10.1093/neuonc/nor223

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Anti-angiogenic therapies, including bevacizumab, are being used with increasing frequency in the management of malignant glioma. Common clinically significant toxicities include hypertension and proteinuria, poor wound healing, and the potential for thromboembolic events. Literature related to the use of bevacizumab in malignant glioma, reported toxicities in this patient population, and management of these toxicities was reviewed. Recommendations for assessment and management are provided. Anti-angiogenic therapies will continue to have a role in the treatment of malignant glioma. Further studies of the prevention, assessment, and management of these toxicities are warranted.

引用

页码：1203 / 1214

页数：12

共 87 条

[1]

Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme [J].

Bacher, M ;

Schrader, J ;

Thompson, N ;

Kuschela, K ;

Gemsa, D ;

Waeber, G ;

Schlegel, J .

AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (01) :11-17

[2]

Management of bevacizumab-associated bowel perforation: a case series and review of the literature [J].

Badgwell, B. D. ;

Camp, E. R. ;

Feig, B. ;

Wolff, R. A. ;

Eng, C. ;

Ellis, L. M. ;

Cormier, J. N. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :577-582

[3]

Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma [J].

Batchelor, Tracy T. ;

Duda, Dan G. ;

di Tomaso, Emmanuelle ;

Ancukiewicz, Marek ;

Plotkin, Scott R. ;

Gerstner, Elizabeth ;

Eichler, April F. ;

Drappatz, Jan ;

Hochberg, Fred H. ;

Benner, Thomas ;

Louis, David N. ;

Cohen, Kenneth S. ;

Chea, Houng ;

Exarhopoulos, Alexis ;

Loeffler, Jay S. ;

Moses, Marsha A. ;

Ivy, Percy ;

Sorensen, A. Gregory ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) :2817-2823

[4]

Bevacizumab Safety in Patients with Central Nervous System Metastases [J].

Besse, Benjamin ;

Lasserre, Susan F. ;

Compton, Peter ;

Huang, Jane ;

Augustus, Stella ;

Rohr, Ulrich-Peter .

CLINICAL CANCER RESEARCH, 2010, 16 (01) :269-278

[5]

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib [J].

Bollee, Guillaume ;

Patey, Natacha ;

Cazajous, Geraldine ;

Robert, Caroline ;

Goujon, Jean-Michel ;

Fakhouri, Fadi ;

Bruneval, Patrick ;

Noel, Laure-Helene ;

Knebelmann, Bertrand .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (02) :682-685

[6]

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis [J].

Carrier, M. ;

Le Gal, G. ;

Tay, J. ;

Wu, C. ;

Lee, A. Y. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (04) :653-663

[7]

AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme [J].

Chinot, O. L. ;

Rouge, T. de la Motte ;

Moore, N. ;

Zeaiter, A. ;

Das, A. ;

Phillips, H. ;

Modrusan, Z. ;

Cloughesy, T. .

ADVANCES IN THERAPY, 2011, 28 (04) :334-340

[8]

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].

Chobanian, AV ;

Bakris, GL ;

Black, HR ;

Cushman, WC ;

Green, LA ;

Izzo, JL ;

Jones, DW ;

Materson, BJ ;

Oparil, S ;

Wright, JT ;

Roccella, EJ .

HYPERTENSION, 2003, 42 (06) :1206-1252

[9]

Chowdhary S, 2008, NAT CLIN PRACT NEURO, V4, P242, DOI 10.1038/ncpneuro0712

[10]

Impact of bevacizumab chemotherapy on craniotomy wound healing Clinical article [J].

Clark, Aaron J. ;

Burowski, Nicholas A. ;

Chang, Susan M. ;

Prados, Michael D. ;

Clarke, Jennifer ;

Polley, Mei-Yin C. ;

Sughrue, Michael E. ;

McDermott, Michael W. ;

Parsa, Andrew T. ;

Berger, Mitchel S. ;

Aghi, Manish K. .

JOURNAL OF NEUROSURGERY, 2011, 114 (06) :1609-1616

← 1 2 3 4 5 6 7 8 9 →